Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 314 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fatty Liver Disease, Nonalcoholic Clear all
Completed Phase 2 Interventional Results available

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

NCT04399538
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
Interventions
PF-06865571, PF-05221304, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Lincoln, California • Montclair, California • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Jul 21, 2026, 3:16 PM EDT
Completed No phase listed Observational

NAFLD Pediatric Database 2

NCT01061684
View directory record Official record
Conditions
Liver Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
2 Years to 17 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers

NCT03610945
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Fluconazole, Quinidine, EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 4 Interventional Results available

Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

NCT01002547
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
pioglitazone-placebo, pioglitazone, Vitamin E, Vitamin E-placebo
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jul 21, 2026, 3:16 PM EDT
Terminated Phase 1Phase 2 Interventional

The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics

NCT00068094
View directory record Official record
Conditions
Fatty Liver, Hepatic Steatosis, Diabetes Mellitus, Liver Diseases
Interventions
Probiotic-containing powder
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jul 21, 2026, 3:16 PM EDT
Not listed No phase listed Observational

Copeptin and Nonalcoholic Fatty Liver Disease

NCT03254563
View directory record Official record
Conditions
NAFLD
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

NCT04173065
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
VK2809, Placebos
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
68
States / cities
Madison, Alabama • Glendale, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 1 Interventional

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

NCT05680233
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Interventions
OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo
Drug
Lead sponsor
Oasis Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

NCT05327127
View directory record Official record
Conditions
NASH
Interventions
K-877-ER, CSG452, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
37
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lincoln, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

NCT03763877
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
PXL770, Placebo Oral Capsule
Drug
Lead sponsor
Poxel SA
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Los Angeles, California • Gainesville, Florida • Ocoee, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 21, 2026, 3:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis

NCT04175392
View directory record Official record
Conditions
Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver, Steatohepatitis, Nonalcoholic
Interventions
Align Probiotic Supplement Capsule, Placebos
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)

NCT01265498
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
obeticholic acid, placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Jul 21, 2026, 3:16 PM EDT
Recruiting Phase 2 Interventional

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07288138
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatohepatitis
Interventions
Placebo, ECC4703, ECC0509
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
62
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Icosabutate in Fatty Liver Disease

NCT04052516
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Icosabutate, Placebo
Drug
Lead sponsor
NorthSea Therapeutics B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
38
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Jul 21, 2026, 3:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Liver in the World Trade Center Health Program General Responder Cohort and Controls

NCT03858920
View directory record Official record
Conditions
Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
Fibroscan of Liver, Low-dose non-contrast CT
Device · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05809934
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 21, 2026, 3:16 PM EDT
Terminated Phase 2 Interventional Results available

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

NCT05211284
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Saroglitazar Magnesium 4 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 21, 2026, 3:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER

NCT04165343
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
Positron Emission Tomography (PET) on EXPLORER, Magnetic Resonance Imaging, Echocardiogram and Electrocardiogram, Blood test
Radiation · Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Not applicable Interventional

Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease

NCT01327443
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Jul 21, 2026, 3:16 PM EDT
Recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

NCT07518784
View directory record Official record
Conditions
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
LiverScope® exam, MR exam, Blood draw, Body measurements, Questionnaire
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH

NCT00267670
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Diseases
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Jul 21, 2026, 3:16 PM EDT
Active, not recruiting No phase listed Observational

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

NCT04595474
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes, Cirrhosis, Liver
Interventions
Transient Elastography
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

NCT02217475
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Cenicriviroc, Placebo
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
40
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Jul 21, 2026, 3:16 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

NCT02933554
View directory record Official record
Conditions
Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions
Embospheres Microspheres
Device
Lead sponsor
Keith Pereira, MD:
Other
Eligibility
22 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jul 21, 2026, 3:16 PM EDT